A method for constructing a high-purity NK cell library

By optimizing the frozen storage and resuscitation system, using specific components of kits and culture media, the problems of NK cell amplification and frozen storage are solved, and effective expansion and frozen storage of high-purity NK cells are achieved, supporting the NK cell bank Establishment and clinical application.

CN116458494BActive Publication Date: 2024-11-05BEIJING JD BIOTECH CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310431278.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-21
Publication Date
2024-11-05
Estimated Expiration
2043-04-21

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively amplify and freeze high-purity NK cells, which leads to challenges in the establishment and clinical application of NK cell banks, especially the difficulty in amplification and sensitive re-scaling after NK cells are resuscited.

Method used

Provide a kit, including cell frozen solution and NK cell amplification medium, which contains DMSO, dextran and human albumin, and the amplification medium contains serum substitutes, IL-2, IL-15. and complex vitamins, optimize the frozen storage and resuscitation system, and achieve efficient frozen storage and resuscitation of NK cells by combining activation medium and amplification medium.

Benefits of technology

Achieving high purity (more than 99%) of NK cells, improving the feasibility of NK cell bank establishment and clinical application, solving the problems of difficulty in amplification and frozen storage after NK cell resuscitation, and providing Efficient storage and utilization methods for NK cell resource.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116458494B_ABST
    Figure CN116458494B_ABST
Patent Text Reader

Abstract

The present invention provides a method for constructing a high-purity NK cell library, the method comprising in vitro expansion of NK cells, magnetic bead sorting of NK cells, cryopreservation of NK cells, and expansion and culture of NK cells after cryopreservation. The technical solution of the present invention enhances the ability of NK cells to expand again after recovery, and has application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and in particular relates to a method for constructing a high-purity NK cell library. Background Art

[0002] Human natural killer (NK) cells account for 15% of all circulating lymphocytes. NK cells were discovered in the 1970s and are primarily associated with killing infected microorganisms and malignantly transformed allogeneic and autologous cells. NK cells exhibit anti-tumor cytotoxicity without prior sensitization and produce cytokines and chemokines that regulate various immune responses. Human peripheral blood NK cells can be divided into two major categories: CD3-CD56bright and CD3-CD56dim. CD56bright NK cells are generally considered to be cytokine-producing cells with low cytotoxicity, while CD56dim NK cells are potentially cytotoxic. Due to the ability of NK cells to recognize and decompose tumor cells, the field of NK cell-based tumor immunotherapy has reached an exciting juncture.

[0003] Although the safety and efficacy of NK cells in clinical applications have been confirmed, since they only account for 5%-15% of peripheral blood lymphocytes, when suffering from tumors, most tumor patients have problems with a decrease in the number of NK cells in their bodies and / or a decrease in the ability of NK cells to eliminate cancer cells, which makes it difficult for their own NK cells to fight against the surge of tumor cells. At this time, it is difficult to achieve satisfactory results by isolating autologous NK cells from the patient's peripheral blood and expanding the culture for adoptive immunotherapy. These have set up obstacles for the clinical application of NK cells. NK cells themselves have no MHC restrictions, and allogeneic use will not produce GVHD. However, other immune cells such as T and B can induce GVHD and host-versus-graft reactions. Therefore, the preparation of high-purity NK cells is crucial. Immunomagnetic bead cell sorting is an efficient and simple method for separating and purifying immune cells. MACS (magnetic-activated cell sorting) sorting is based on the ability of cell surface antigens to bind to specific monoclonal antibodies connected to magnetic beads. In an external magnetic field, cells connected to magnetic beads through antibodies are adsorbed and retained in the sorting column, while cells without such surface antigens cannot bind to specific monoclonal antibodies connected to magnetic beads and have no magnetism, so they do not stay in the sorting column, thereby allowing the cells to be separated. MACS microbeads are superparamagnetic particles coupled to highly specific monoclonal antibodies. Negative magnetic bead sorting can obtain high-purity target cells by marking the impurity cells that need to be removed through microbeads.

[0004] In order to facilitate people to effectively store and use tissue and cell resources, a variety of cell banks or tissue banks have been established around the world, such as cord blood hematopoietic stem cell banks, mesenchymal stem cell banks, etc. The establishment of a peripheral blood-derived NK cell bank can, on the one hand, increase the NK cell expansion multiple through multiple rounds of expansion; on the other hand, the NK cell bank provides convenience for KIR and HLA matching, so that patients can use the best NK cells.

[0005] NK cells have limited proliferation potential, and in vitro expansion is a challenge. In recent years, studies on NK cell expansion and culture generally use two methods: adding trophoblast cells and pure factor culture. Adding trophoblast cells can better activate NK cells and expand them in large quantities, but even if the added trophoblast cells have been irradiated, there is still a great risk and they are not suitable for clinical use; using the pure factor method to induce the expansion of NK cells in PBMC is safer and suitable for clinical use, but the expansion multiples are generally not ideal. In addition, the reinfusion of allogeneic NK cells requires complete elimination of T cells to avoid GVHD; it is undoubtedly an extremely difficult task to use the pure factor method to expand in large quantities and obtain highly active NK cells with a purity greater than 99%.

[0006] Terminally differentiated NK cells from peripheral blood are highly sensitive to cryopreservation. NK cells cryopreserved in existing commercial cryopreservation solutions have weak re-expansion capabilities when cultured using conventional methods, which makes the establishment of NK cell banks a huge challenge.

[0007] References:

[0008] 1.CAR-expressing NK cells for cancer therapy:a newhope.BiosciTrends.2020 Sep 6.

[0009] 2. Beatriz Cózar et al, Tumor-infiltrating natural killer cells, CancerDiscov. 2021 January 01; 11(1):34–44.

[0010] 3.Kiessling R,Klein E,Wigzell H. “Natural” killer cells in themouse.I.Cytotoxic cells with specificity for mouse Moloney leukemiacells.Specificity and distribution according to genotype.Eur J Immunol.1975;5:112–7.

[0011] 4.Martha Luevano et al, The unique profile of cord blood natural killercells balances incomplete maturation and effective killing function upon activation, Human Immunology 73 (2012) 248-257.

[0012] 5. Jacob A. Myers, Jeffrey S. Miller; Exploring the NK cell platform for cancer immunotherapy, Nat Rev Clin Oncol, 2021February, 18(2):85-100.

[0013] 6. Ying Gong et al, Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy, J Hematol Oncol (2021) 14:73. Summary of the invention

[0014] The first purpose of the present invention is to provide a method for constructing a high-purity NK cell library to solve the problem of difficulty in re-expanding NK cells after recovery.

[0015] The second object of the present invention is to provide an optimized NK cell freezing system and recovery culture system.

[0016] To achieve the above object, the present invention adopts the following technical solutions:

[0017] The first aspect of the present invention provides a kit for freezing and resuscitating NK cells, the kit comprising a cell freezing solution and a NK cell expansion medium, the NK cell expansion medium comprising the following components:

[0018] Serum replacement, IL-2, IL-15, multivitamins.

[0019] NK cells (natural killer cells): As used herein, "natural killer cells" or NK cells are lymphoid cells defined by their marker expression and function / activity. For example, in humans, NK cells express CD56. In additional embodiments, such NK cells may express CD56 and CD16. In another example, such NK cells may be CD56+ / CD3- cells. NK cells may express variable levels of CD56. For example, NK cells may be "CD56high," which means that NK cells express high levels of CD56, as assessed by methods of the art, such as by flow cytometry. As another example, NK cells may be "CD56dim," which means that NK cells express low but detectable levels of CD56, as assessed by methods of the art, such as by flow cytometry.

[0020] As used herein, the term "medium" refers to a liquid substance used to support cell growth. In some embodiments, the culture may be a liquid (e.g., water) based medium or may include a combination of, for example, salts, nutrients, minerals, vitamins, amino acids, nucleic acids, proteins, such as cytokines, growth factors, and hormones.

[0021] Further, the cell freezing solution comprises the following components:

[0022] DMSO, dextran, human albumin, compound electrolyte solution.

[0023] According to the embodiments of the present invention, the source of human albumin is not particularly limited, as long as human albumin can be provided, that is, it can be derived from commercially available human serum albumin or human plasma. Human mononuclear cells have little rejection effect on human serum albumin or plasma, which is conducive to the recovery of cryopreserved cells.

[0024] Furthermore, the vitamin complex comprises one or more of vitamin A / retinol, vitamin B2 / vitamin B6 / vitamin B12, and vitamin C / L-ascorbic acid. In a specific embodiment of the present invention, the vitamin complex is a complex of vitamin C and vitamin B2. As a preferred embodiment, in the vitamin complex, vitamin C:vitamin B2=1:9.

[0025] Ascorbic acid or vitamin C: "Ascorbic acid" or "vitamin C" as used herein refers to L-ascorbic acid and its derivatives, and "L-ascorbic acid derivatives" means derivatives that become vitamin C by an enzymatic reaction in a living body. Examples of L-ascorbic acid derivatives include vitamin C phosphate, ascorbyl glucoside, ascorbic acid ethyl ester, vitamin C ester, ascorbic acid tetrahexyldecanoate, ascorbyl stearate, and ascorbic acid 2-phosphate 6-palmitate. Examples of vitamin C phosphate include salts of L-ascorbic acid phosphate, such as L-ascorbic acid phosphate Na and L-ascorbic acid phosphate Mg. In one embodiment, vitamin C can be ascorbic acid 2-phosphate.

[0026] In the present invention, the term "serum replacement" refers to an agent used for the culture of cells as a substitute for serum (e.g., FBS) in cell culture. Examples of serum replacements include KNOCKOUTTMSR (KnockOutTM serum replacement or KSR; Gibco), StemSure serum replacement (SSR; WakoPureChemicalIndustries, Ltd.), N-2 supplement (WakoPureChemicalIndustries, Ltd.), CTS TM Immune cell serum replacement.

[0027] Further, in the NK cell expansion medium, the serum substitute is CTS TM Immune cell serum replacement.

[0028] Further, in the NK cell expansion medium, the concentration of serum replacement is 3%-10%, the concentration of IL-2 is 1000-10000 IU / mL, the concentration of IL-15 is 50-2000 IU / mL, and the concentration of multivitamins is 100-1000 ng / mL. In a specific embodiment of the present invention, the concentration of serum replacement is 5%, the concentration of IL-2 is 1000 IU / mL, the concentration of IL-15 is 300 IU / mL, and the concentration of multivitamins is 100 ng / mL.

[0029] Furthermore, the basal culture medium of the NK cell expansion culture medium is selected from NK MACS, X-VIVO15, GT-T551H3, cellgrowSCGM, AIM-V. In a specific embodiment of the present invention, the basal culture medium of the NK cell expansion culture medium is NKMACS.

[0030] Further, in the freezing solution, the concentration of DMSO is 10%, the concentration of dextran is 0-10%, the concentration of human albumin is 40%-50%, and the concentration of the compound electrolyte solution is 40%-50%. In a specific embodiment of the present invention, the concentration of human albumin is 40%, the concentration of dextran is 10%, and the concentration of the compound electrolyte solution is 40%.

[0031] Furthermore, the human serum albumin can be replaced by autologous plasma. Furthermore, in the cryopreservation solution, the concentration of the autologous plasma is 40%-50%, preferably, the concentration of the autologous plasma is 40%.

[0032] The term "autologous plasma" as used herein refers to plasma from the same source as the cells to be induced, expanded and cryopreserved. In other words, the plasma and the mononuclear cells to be induced, expanded are taken from the same individual. As a result, the rejection effect on the autologous immune cells is small, which is beneficial to the protection of the cryopreserved cells.

[0033] Furthermore, the compound electrolyte solution can be replaced by sodium chloride injection. Furthermore, in the cryopreservation solution, the concentration of sodium chloride injection is 40%-50%, preferably, the concentration of sodium chloride injection is 40%.

[0034] A second aspect of the present invention provides a method for preserving NK cells, the method comprising:

[0035] The NK cells to be stored are mixed with a cell freezing solution and then cryopreserved, wherein the cell freezing solution is as defined in the first aspect of the present invention.

[0036] The third aspect of the present invention provides a method for NK cell proliferation and culture after recovery, the method comprising:

[0037] The NK cells to be revived are thawed, and the thawed NK cells are mixed with a NK cell expansion medium and then cultured. The NK cell expansion medium is as defined in the first aspect of the present invention.

[0038] A fourth aspect of the present invention provides a method for constructing a NK cell library, the method comprising:

[0039] (1) Pretreating the cell culture vessel with a coating solution;

[0040] (2) obtaining mononuclear cells;

[0041] (3) in the cell culture container obtained in 1), using an activation medium for activating the mononuclear cells in 2), wherein the activation medium comprises a serum replacement, IL-2, IL-15, IL-21, CD137 antibody, CD3 antibody, and multivitamins;

[0042] (4) supplementing the first expansion medium, wherein the first expansion medium includes serum replacement, IL-2, IL-15, IL-21, and multivitamins;

[0043] (5) supplementing NK cell expansion medium, wherein the NK cell expansion medium is as defined in claim 1, to obtain expanded mononuclear cells;

[0044] (6) Using magnetic beads, the amplified mononuclear cells obtained in 5) are sorted to obtain NK cells.

[0045] Furthermore, the coating solution includes CD137 antibody, CD28 antibody, and CD3 antibody. In a specific embodiment of the present invention, the concentration of CD137 antibody is 8 μg / mL, the concentration of CD28 antibody is 8 μg / mL, and the concentration of CD3 antibody is 8 μg / mL;

[0046] Further, in the activation medium, the concentration of IL-2 is 1000-10000 IU / mL, the concentration of IL-15 is 50-2000 IU / mL, the concentration of IL-21 is 0.1-5 IU / mL, the concentration of CD3 antibody is 5-15 μg / mL, the concentration of CD137 antibody is 5-15 μg / mL, the concentration of multivitamins is 0-1000 ng / mL, and the concentration of serum substitute is 3-10%. In the specific implementation of the present invention, in the activation medium, the concentration of IL-2 is 1000 IU / mL, the concentration of IL-15 is 300 IU / mL, the concentration of IL-21 is 0.2 IU / mL, the concentration of CD3 antibody is 5 μg / mL, the concentration of CD137 antibody is 5 μg / mL, the concentration of multivitamins is 100 ng / mL, and the concentration of serum substitute is 5%;

[0047] Furthermore, in the first amplification medium, the concentration of IL-2 is 1000-10000 IU / mL, the concentration of IL-15 is 50-2000 IU / mL, the concentration of IL-21 is 0.1-5 IU / mL, the concentration of multivitamins is 0-1000 ng / mL, and the concentration of serum replacement is 3-10%. In a specific embodiment of the present invention, in the first amplification medium, the concentration of serum replacement is 5%, the concentration of IL-2 is 1000 IU / mL, the concentration of IL-15 is 300 IU / mL, the concentration of IL-21 is 0.2 IU / mL, and the concentration of multivitamins is 100 ng / mL.

[0048] Furthermore, the vitamin complex in the activation medium and the first expansion medium independently comprises one or more of vitamin A / retinol, vitamin B2 / vitamin B6 / vitamin B12, and vitamin C / L-ascorbic acid. In a specific embodiment of the present invention, the vitamin complex is a complex of vitamin C and vitamin B2. As a preferred embodiment, in the vitamin complex, vitamin C: vitamin B2 = 1:9.

[0049] Furthermore, the serum replacement in the activation medium and the first expansion medium is independently CTS TM Immune cell serum replacement.

[0050] Furthermore, the activation medium and the first expansion medium are each independently selected from the following basal medium: NKMACS, X-VIVO15, GT-T551H3, cellgrowSCGM, AIM-V. Preferably, the basal medium of the activation medium and the first expansion medium is each independently NKMACS.

[0051] Furthermore, the mononuclear cells are obtained from peripheral blood, single blood, umbilical cord blood or bone marrow samples. Preferably, the mononuclear cells are obtained from peripheral blood.

[0052] Furthermore, the method for obtaining mononuclear cells is a density gradient method, and preferably, the separation fluid of the density gradient method is Ficoll.

[0053] Furthermore, the magnetic beads include CD3, CD14, and CD19.

[0054] Furthermore, the amount of magnetic beads used was 20 μL / 10 7 cell.

[0055] Furthermore, the method also includes using the kit described in the first aspect of the present invention for the cryopreservation and recovery of NK cells.

[0056] The fifth aspect of the present invention provides a product, which comprises NK cells obtained by the method described in the third aspect of the present invention or the fourth aspect of the present invention.

[0057] Furthermore, the purity of the NK cells is above 95%, 96%, 97%, 98%, or 99%.

[0058] The sixth aspect of the present invention provides the use of the product of the fifth aspect of the present invention in the preparation of a preparation for killing tumor cells. In a specific embodiment of the present invention, the tumor cells are K562-LUC.

[0059] The seventh aspect of the present invention provides the use of the product described in the fifth aspect of the present invention in the preparation of a drug for cell therapy, a drug for antiviral infection, or a drug for treating cancer or autoimmune diseases;

[0060] The use also includes application in combined therapy with antibody drugs, nucleic acid drugs, small molecule drugs, oncolytic virus drugs and cell drugs; application in combined therapy with NK cells and radiotherapy, chemotherapy drugs, stem cell transplantation surgery, interventional therapy, ablation therapy and other treatment methods;

[0061] Preferably, the cancer comprises acute lymphocytic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytoma, atypical teratoid / rhabdoid tumor, bile duct cancer, extrahepatic bladder cancer, bone cancer, brain stem glioma, brain cancer, breast cancer, bronchial tumor, Burkitt's lymphoma, carcinoid tumor, heart tumor, central nervous system cancer, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorder, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, bile duct cancer, embryonal tumor, endometrial cancer , ependymoma, esophageal cancer, nasal glioma, Ewing's sarcoma, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer, bone fibrous histiocytoma, gallbladder cancer, gastric cancer, germ cell tumor, gestational trophoblastic disease, glioma, head and neck cancer, heart cancer, hepatocellular carcinoma, histiocytosis, Langerhans cell, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumor, pancreatic neuroendocrine tumor, Kaposi's sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, , lip and oral cancer, liver cancer, lobular carcinoma in situ, lung cancer, lymphoma, melanoma, mesothelioma, Occult Primary Metastatic Squamous Neck Cancer, Oral Cancer, Multiple Endocrine Neoplasia Syndrome in Children, Multiple Myeloma / Plasma Cell Neoplasia, Mycosis Fungoides, Myelodysplastic Syndrome, Myelodysplastic / Myeloproliferative Neoplasia, Multiple Myeloma, Myeloproliferative Disorders, Nasal and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Pancreatic Neuroendocrine Tumors, Papillomatosis, Paraganglioma, Paranasal Sinus and Nasal Cancer, Parathyroid Cancer, Penile Cancer, Pharyngeal Cancer, Pituitary Tumors, Plasma Cell Neoplasia / Multiple Osteoarthritis Myeloma, pleuropulmonary blastoma, pregnancy and breast cancer, primary central nervous system lymphoma, prostate cancer, colorectal cancer, kidney cancer, transitional cell carcinoma of the renal pelvis and ureter, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, occult primary metastatic squamous neck cancer, gastric cancer, T-cell lymphoma, testicular cancer, laryngeal cancer, thymoma and thymic cancer, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, urethral cancer, uterine cancer, endometrium, uterine sarcoma, vaginal cancer, vulvar cancer Wilms' tumor.

[0062] "Treating" a disease or condition refers to carrying out a regimen, which may include administering one or more drugs or cell therapy products to a patient, in an effort to alleviate the signs or symptoms of the disease. Desired therapeutic effects include reducing the rate of disease progression, ameliorating or alleviating the disease state, and alleviating or improving prognosis. Alleviation may occur before signs or symptoms of the disease or condition appear as well as after they appear. Thus, "treating" may include "preventing" a disease or undesirable condition. In addition, "treating" does not require complete alleviation of signs or symptoms, does not require a cure, and specifically includes regimens that have only a marginal effect on the patient.

[0063] "Autoimmune disease" refers to a disease in which the immune system generates an immune response (e.g., a B cell or T cell response) against an antigen that is a normal part of the host (i.e., a self-antigen) and subsequently damages the tissue. The self-antigen may be derived from host cells, or may be derived from commensal organisms, such as microorganisms that typically colonize mucosal surfaces (referred to as commensal organisms).

[0064] Preferably, the autoimmune diseases include Addison's disease, alopecia areata, ankylosing spondylitis, autoimmune hepatitis, autoimmune mumps, Crohn's disease, type 1 diabetes, dystrophic epidermolysis bullosa, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, hemolytic anemia, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis, vasculitis, vitiligo, myxedema, pernicious anemia, ulcerative colitis, and the like.

[0065] Beneficial Effects

[0066] The NK cell culture method provided by the present invention can obtain NK cells with a purity of more than 99%. The present invention can effectively solve the problem of difficulty in obtaining high-purity NK cells, and provides the possibility for the allogeneic use of NK cells separated and cultured from peripheral blood. The present invention can realize the construction of a human NK cell bank, and the healthy or young NK cells of humans are built into a bank by a certain method. It is an effective method for fully preserving and utilizing existing NK cell resources. It provides strong support for storing autologous or allogeneic cells when immune cell therapy technology is needed, which is of great significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0067] Figure 1 This is the proliferation curve of NK cells cultured to day 13;

[0068] Figure 2 The flow cytometry results of NK cells before and after magnetic bead sorting on day 13, where Figure A is the flow cytometry result of NK cells before sorting, and Figure B is the flow cytometry result of NK cells after sorting;

[0069] Figure 3 This is a statistical chart showing the killing effect of NK cells on K562 cells before and after cryopreservation;

[0070] Figure 4 This is the flow cytometry result of NK cells on day 0 after recovery;

[0071] Figure 5 This is a statistical chart of NK cell expansion capacity after 23 days of recovery culture;

[0072] Figure 6 This is the flow cytometry result of NK cells recovered and cultured for 23 days;

[0073] Figure 7 This is a statistical chart of the killing effect of NK cells on K562 cells after 23 days of resuscitation and culture;

[0074] Figure 8 The figure is a comparison of the killing effect of CS10 and JD-CF1 cryopreserved NK cells on K562 cells after recovery;

[0075] Fig. 9 The figure shows the comparison of the expansion capacity of NK cells frozen in CS10 and JD-CF1 after recovery;

[0076] Fig.10 The figure shows the comparison of the viability of NK cells frozen in CS10 and JD-CF1 after recovery;

[0077] Fig.11 This is a comparison of the expansion capacity of NK cells after recovery using different culture processes;

[0078] Fig.12 This is a comparison of cell viability results after NK cell recovery using different culture processes. DETAILED DESCRIPTION

[0079] The present invention will be described in detail below in conjunction with embodiments and drawings, so that those skilled in the art can understand and implement the present invention and further recognize the advantages of the present invention.

[0080] Unless otherwise defined in the specification of the present invention, all technical terms herein are used according to the customary definitions commonly used and understood by those skilled in the art. The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0081] Example 1 Expansion, cryopreservation and recovery of NK cells

[0082] 1. NK cell expansion and cryopreservation process

[0083] Experimental methods:

[0084] 1. Pretreatment of cell culture flasks

[0085] Add 6.5 ml of saline solution containing 8 μg / mL CD137 monoclonal antibody, 8 μg / mL CD28 monoclonal antibody, and 8 μg / mL CD3 monoclonal antibody to 75 cm 2 Place the cells in a cell culture flask with a large bottom area and allow the liquid to fully disperse at the bottom of the flask, then place flat at 4°C overnight.

[0086] 2. Isolation of Peripheral Blood Mononuclear Cells (PBMCs)

[0087] Take 40mL peripheral blood as an example. If the blood volume is different, you can make corresponding adjustments according to this operation. 40mL of the patient's sterile peripheral blood after plate testing is centrifuged in a low-speed differential centrifuge at room temperature for 30 minutes, 9% up and 7% down, to separate plasma and blood cells.

[0088] The upper plasma was transferred to a centrifuge tube, inactivated at 56°C for 30 min, centrifuged at 2000 rpm for 10 min, and the supernatant was taken and stored at 4°C for later use.

[0089] The blood cell pellet was mixed with an equal volume of saline and peripheral blood mononuclear cells (PBMC) were separated by Ficoll density gradient centrifugation. Specifically, the above mixture was carefully added to a 50 mL centrifuge tube containing a Ficoll layer and subjected to differential centrifugation at room temperature for 20 minutes. The PBMC layer was aspirated, and the cell layer at the junction of the two liquid surfaces was aspirated as much as possible, and saline was added to mix by pipetting, and centrifuged at room temperature at 1500 rpm for 10 minutes. The cells were washed again with saline.

[0090] After discarding the supernatant, resuspend the cells in 10 mL of buffer and adjust the volume to 20 mL. Take a small amount of cells for counting.

[0091] 3. Inoculation

[0092] According to 2.0×10 6 The PBMC cells obtained in step 2 were inoculated into medium containing 5% serum replacement (CTS) at a cell concentration of 100 cells / ml. TM The cells were placed in a coated culture flask obtained in step 1 of 12 mL NK MACS (Miltenyi) medium containing 1000 IU / mL of immune cell serum replacement, IL-2, 300 IU / mL of IL-15, 0.2 IU / mL of IL-21, 75 μg / mL of CD13, 5 μg / mL of CD3, and 100 ng / mL of multivitamins (vitamin C: vitamin B2 = 1:9). The cells were cultured in an incubator (37°C, 5% CO2 concentration, 45%-55%).

[0093] 4. First rehydration

[0094] On the third day after cell inoculation, the cells were replenished with 12 mL of fluid. At this time, the supplemented medium was expansion medium 1 (basal medium was NK MACS) containing 5% serum replacement, IL-2 1000 IU / mL, IL-15 300 IU / mL, IL-2 10.2 IU / mL, and multivitamins (vitamin C: vitamin B2 = 1:9) 100 ng / mL.

[0095] 5. Second fluid refill

[0096] On the 5th day of culture, the second supplementation was performed with a volume of 12 mL. At this time, the supplemented medium was expansion medium 2 (basal medium was NK MACS) containing 5% serum replacement, IL-2 1000 IU / mL, IL-15 300 IU / mL, and multivitamins 100 ng / mL.

[0097] 6. Third fluid replenishment

[0098] On the 5th day of culture, the second supplementation was performed with a volume of 12 mL. At this time, the supplemented medium was expansion medium 2 (basal medium was NK MACS) containing 5% serum replacement, IL-2 1000 IU / mL, IL-15 300 IU / mL, and multivitamins 100 ng / mL.

[0099] 7. Fourth fluid replenishment

[0100] On the 7th day, the cell density was measured and the cell density was calculated as 1×10 6 The cell culture flask was placed in an incubator and the culture was continued at a cell density of 100 cells / mL.

[0101] 8. Fifth fluid replenishment

[0102] On day 9, the cell density was measured and the cell density was calculated as 1×10 6 The cell culture flask was placed in an incubator and the culture was continued at a cell density of 100 cells / mL.

[0103] 9. Sixth fluid replenishment

[0104] On day 11, the cell density was measured and the cell density was calculated as 1×10 6 The cell culture flask was placed in an incubator and the culture was continued at a cell density of 100 cells / mL.

[0105] 10. NK cell sorting

[0106] On the 13th day of cell culture, the cell suspension was filtered through a 70 μm cell mesh to remove cell clusters, and samples were counted. The amount of Macs-buffer and magnetic beads was calculated based on the counting results, and magnetic bead negative selection of CD3, CD14, and CD19 was performed. The amount of magnetic beads was 20 μL / 10 7 cell.

[0107] 11. NK cell cryopreservation

[0108] The freezing solution was named JD-CF1, and its formula was 10% DMSO+10% dextran+40% human albumin+40% compound electrolyte solution.

[0109] (1) Collect the cell suspension and centrifuge at 400g for 10 min at room temperature to collect the cells;

[0110] (2) centrifugation with physiological saline at 400 g for 10 min at room temperature to wash the cell pellet;

[0111] (3) Resuspend the cell pellet with saline and filter through a 70 μm cell sieve; centrifuge at 400 g for 10 min at room temperature to collect the cells;

[0112] (4) Remove the supernatant and remove as much supernatant as possible to reduce the dilution degree of the cryopreservation solution;

[0113] (5) Take an appropriate amount of pre-cooled (2-8°C) JD-CF1 cryopreservation solution to resuspend the cells, stain with AOPI and count the cells. 7 cells / mL freezing density was added to pre-cooled (2-8°C) JD-CF1 freezing solution;

[0114] (6) The cell / cryopreservation solution suspension was dispensed into cryotubes and immediately placed in a pre-cooled (2-8°C) isopropanol gradient cooling box;

[0115] (7) After being placed in the isopropanol cooling box at -80°C for 18-24 hours, the frozen cells were removed and transferred to liquid nitrogen for storage as soon as possible.

[0116] Experimental Results

[0117] On the 13th day of cell culture, the cell density was 2.76×10 6 , cell expansion times 25 times (such as Figure 1 shown).

[0118] The purity of NK cells obtained after sorting was 99% ( Figure 2 shown).

[0119] 2. NK cell expansion and culture process after recovery:

[0120] Experimental methods

[0121] 1. NK cell recovery

[0122] Take out the cells from the liquid nitrogen tank and quickly immerse the cryotube in a 37°C constant temperature water bath to thaw it as quickly as possible. After it is completely thawed, quickly transfer the mixed cell suspension to a 15mL centrifuge tube that has been added with 10mL of Expansion Medium 2, and centrifuge at 400g for 10min at room temperature. After centrifugation, remove the supernatant and add 10mL of Expansion Medium 2 to resuspend the cells.

[0123] 2. NK cell inoculation

[0124] The cell seeding density was 1.0 × 10 6 / mL, and inoculated with expansion medium 2.

[0125] Expansion medium 2 is NK MACS (Miltenyi) medium containing 5% serum replacement, IL-2 1000 IU / mL, IL-15 300 IU / mL, and multivitamins 100 ng / mL.

[0126] 3. Fluid rehydration

[0127] The first rehydration was performed on the third day after cell inoculation, and the cell density was adjusted to 1.0 × 10 6 / mL. Count and replenish the solution every other day to ensure that the cell density is 1.0×10 6 The supplemented medium was expansion medium 2.

[0128] Experimental Results

[0129] On the 23rd day after cell inoculation, the cell proliferation was 52-fold.

[0130] The killing effect of NK cells on K562 cells before and after cryopreservation Figure 3 shown.

[0131] NK cell flow cytometry results on day 0 after resuscitation Figure 4 shown.

[0132] The proliferation capacity of NK cells after 23 days of recovery culture Figure 5 shown.

[0133] The flow cytometry results of NK cells after 23 days of recovery culture are as follows Figure 6 shown.

[0134] Example 2 Detection of cell killing activity after NK cell recovery

[0135] Experimental methods

[0136] 1. Preparation of Calcein-AM working solution: Use DMSO to prepare the detection solution into a working solution with a concentration of 1 μg / ml.

[0137] 2. Target cell preparation:

[0138] (1) Collect target cells K562-LUC by centrifugation at 400G for 5 min at room temperature;

[0139] (2) Resuspend the cells in NK basal medium (equilibrated to room temperature) and adjust the target cell density to 1×10 6 cells / ml;

[0140] (3) Every 1×10 6 Add 7.5 μL Calcein-AM working solution to each cell and incubate in a 37°C incubator for 30 min, mixing 1 to 2 times in the middle;

[0141] (4) After staining, the cells were collected by centrifugation at 400g for 5 min at room temperature and washed twice with PBS (equilibrated to room temperature);

[0142] (5) Resuspend the cells in NK basal medium (equilibrated to room temperature) and adjust the target cell density to 2×10 5 cells / ml.

[0143] 3. Effector Cell Preparation

[0144] (1) Take an appropriate amount of NK cells from 2.4 and collect the cells by centrifugation at room temperature;

[0145] (2) Resuspend the cells in NK basal medium (equilibrated to room temperature);

[0146] (3) Adjust the effector cell density to 2×10 6 cells / ml.

[0147] 4. Add effector cells and target cells to a 96-well cell culture plate as follows:

[0148] Spontaneous pores: 100 μL culture medium + 100 μL target cells

[0149] Maximum well: 100 μL target cells + 50 μL NK basal medium

[0150] Experimental well: 100 μL target cells + 100 μL effector cells

[0151] 5. Place the cells in a 37°C incubator in the dark for 4 hours. After incubation, remove the cell culture plate and add 50 μL 0.4% Triton@ to the maximum release well.

[0152] Centrifuge at 6.400g for 5 min at room temperature, transfer 150 μL of supernatant to an ELISA plate, and detect on an analyzer.

[0153] Experimental results:

[0154] The killing effect of NK cells on K562 cells after 23 days of resuscitation Figure 7 shown.

[0155] Example 3 Comparison of two cryopreservation processes

[0156] The NK cells cultured in the test example (i.e., Example 1) were cryopreserved with the cryopreservation solution JD-CF1, and the cryopreservation solution CS10 in the comparative example 1 was used as a control. The cell number and cell viability before and after cell cryopreservation, in vitro killing activity, and proliferation ability after resuscitation were evaluated to compare the effects of the two cryopreservation solutions on the activity of NK cells after cryopreservation.

[0157] The culture and cryopreservation process of NK cells in Comparative Example 1 is different from that in the test example only in the cryopreservation solution used. The cryopreservation solution used in this comparative example is: clinical grade ready-to-use cryopreservation solution CS10.

[0158] The results show:

[0159] After the cells were revived in different cryopreservation solutions, the cell viability decreased slightly, with no significant difference. The cell number was lost, and the cell recovery rate in the JD-CF1 group was more stable than that in the CS10 group (as shown in Table 1).

[0160] Table 1 Comparison of NK cell viability before and after cryopreservation

[0161]

[0162] After resuscitation, in vitro killing activity, such as Figure 8 As shown, the killing activity of JD-CF1 group was significantly higher than that of CS10 group.

[0163] After cell recovery, the cells were cultured in vitro. The results showed that the proliferation ability and viability of cells in the JD-CF1 group were significantly better than those in the CS10 group (e.g. Figure 9-10 shown).

[0164] The NK cell culture and cryopreservation process of the present invention is superior to the comparative example process.

[0165] Example 4 Comparison of the effects of different processes on the activity of NK cells after resuscitation

[0166] After NK cells were resuscitated, the culture process after resuscitation in Comparative Example 2 was used as a control to compare the effects of different culture processes on the activity of NK cells after resuscitation.

[0167] Test example: NK cell recovery and expansion culture process:

[0168] 1. NK cell recovery

[0169] Take out the cells from the liquid nitrogen tank and quickly immerse the cryotube in a 37°C constant temperature water bath to thaw it as quickly as possible. After it is completely thawed, quickly transfer the mixed cell suspension to a 15ml centrifuge tube that has been added with 10mL of Expansion Medium 2, and centrifuge at 400g for 10min at room temperature. After centrifugation, remove the supernatant and add 10mL of Expansion Medium 2 to resuspend the cells.

[0170] 2. NK cell inoculation

[0171] The cell seeding density was 1.0 × 10 6 / mL, and inoculated with expansion medium 2.

[0172] Expansion medium 2 is NK MACS (Miltenyi) medium containing 5% serum replacement, IL-2 1000 IU / mL, IL-15 300 IU / mL, and multivitamins 100 ng / mL.

[0173] 3. Fluid rehydration

[0174] The first rehydration was performed on the third day after cell inoculation, and the cell density was adjusted to 1.0 × 10 6 / mL. Count and replenish the solution every other day to ensure that the cell density is 1.0×10 6 The supplemented medium was expansion medium 2.

[0175] Comparative Example 2 NK cell recovery and expansion culture process:

[0176] The difference between the NK cell recovery culture process provided in this comparative example and the test example is only that the expansion medium used is different. The formula of the expansion medium used in this comparative example: NK MACS (Miltenyi) medium containing 5% serum replacement, IL-2 1000IU / mL, IL-15 10ng / mL, IL-21 100ng / mL.

[0177] The results show that: Fig.11 , 12 As shown, the expansion capacity of the NK cell recovery and expansion culture process of the present invention is significantly better than that of the comparative example process.

[0178] Although the present invention has been described with reference to the accompanying drawings and preferred embodiments, various modifications and variations of the present invention are apparent to those skilled in the art. Various modifications, variations, and equivalents of the present invention are covered by the appended claims.

Claims

1. A kit for freezing and resuscitating NK cells, the kit comprising a cell freezing solution and a NK cell expansion medium; The NK cell expansion medium is a medium containing 5% serum replacement, 1000 IU / mL IL-2, 300 IU / mL IL-15, and 100 ng / mL complex vitamins, wherein the serum replacement is CTS™ immune cell serum replacement, and the complex vitamins are a complex of vitamin C and vitamin B2, wherein: Vitamin C: Vitamin B2 = 1:9; The cell freezing solution is a solution containing 10% DMSO, 10% dextran, 40% human serum albumin, and 40% compound electrolyte solution.

2. The kit according to claim 1, characterized in that The basal culture medium of the NK cell expansion culture medium is NK MACS.

3. A method for amplifying and culturing NK cells after recovery, characterized in that: The method includes: Thawing the NK cells to be revived, mixing the thawed NK cells with NK cell expansion medium and then culturing; Wherein, the NK cell expansion medium is as defined in claim 1.

4. A method for constructing a NK cell library, characterized in that: The method includes: (1) pretreating a cell culture container with a coating solution; the coating solution comprises CD137 antibody, CD28 antibody, and CD3 antibody, wherein the concentration of the CD137 antibody is 8 μg / mL, the concentration of the CD28 antibody is 8 μg / mL, and the concentration of the CD3 antibody is 8 μg / mL; (2) Obtaining mononuclear cells; (3) In the cell culture container obtained in 1), an activation medium is used for activating the mononuclear cells in 2), wherein the activation medium comprises a serum replacement, IL-2, IL-15, IL-21, CD137 antibody, CD3 antibody, and multivitamins; the multivitamins are a complex of vitamin C and vitamin B2, and the ratio thereof is 1:9; the serum replacement is CTS™ immune cell serum replacement; in the activation medium, the concentration of IL-2 is 1000 IU / mL, the concentration of IL-15 is 300 IU / mL, the concentration of IL-21 is 0.2 IU / mL, the concentration of CD3 antibody is 5 μg / mL, the concentration of CD137 antibody is 5 μg / mL, the concentration of multivitamins is 100 ng / mL, and the concentration of serum replacement is 5%; (4) Supplementing the first expansion medium, wherein the first expansion medium comprises serum replacement, IL-2, IL-15, IL-21, and multivitamins; the multivitamin is a complex of vitamin C and vitamin B2, the ratio of which is 1:9, the serum replacement is CTS™ immune cell serum replacement, and in the first expansion medium, the concentration of serum replacement is 5%, the concentration of IL-2 is 1000 IU / mL, the concentration of IL-15 is 300 IU / mL, the concentration of IL-21 is 0.2 IU / mL, and the concentration of multivitamins is 100 ng / mL; (5) supplementing NK cell expansion medium, wherein the NK cell expansion medium is as defined in claim 1, to obtain expanded mononuclear cells; (6) Using magnetic beads to sort the amplified mononuclear cells obtained in 5) to obtain NK cells; the magnetic beads include CD3, CD14, and CD19, and the amount of the magnetic beads is 20 μL / 10 7 cell.

5. The method according to claim 4, characterized in that The activation medium and the basic medium of the first expansion medium are each independently NK MACS.

6. The method according to claim 4, characterized in that The mononuclear cells are obtained from peripheral blood.

7. The method according to claim 4, characterized in that The method for obtaining mononuclear cells is a density gradient method, and the separation liquid of the density gradient method is Ficoll.

8. The method of claim 4, wherein the supplemented first expansion medium is added on day 3.

9. The method of claim 4, wherein the supplemented NK cell expansion medium is added on days 5, 7, 9, and 11.

10. The method according to any one of claims 4 to 9, characterized in that: The method also includes using the kit according to claim 1 for the cryopreservation and recovery of NK cells.

Citation Information

Cited By

  • Method and kit for separating and purifying natural killer cells

    CN120574772A